5G3 Stock Overview
An investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, India, New Zealand, Australia, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
TalkMed Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.46 |
| 52 Week High | S$0.50 |
| 52 Week Low | S$0.35 |
| Beta | 0.17 |
| 11 Month Change | -7.14% |
| 3 Month Change | 16.67% |
| 1 Year Change | 16.67% |
| 33 Year Change | 12.35% |
| 5 Year Change | -10.78% |
| Change since IPO | 10.98% |
Recent News & Updates
Shareholder Returns
| 5G3 | SG Healthcare | SG Market | |
|---|---|---|---|
| 7D | 1.1% | 0.4% | 0.5% |
| 1Y | 16.7% | -11.7% | 14.1% |
Return vs Industry: 5G3 exceeded the SG Healthcare industry which returned -11.7% over the past year.
Return vs Market: 5G3 exceeded the SG Market which returned 14.1% over the past year.
Price Volatility
| 5G3 volatility | |
|---|---|
| 5G3 Average Weekly Movement | 5.8% |
| Healthcare Industry Average Movement | 5.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in SG Market | 14.4% |
| 10% least volatile stocks in SG Market | 2.1% |
Stable Share Price: 5G3 has not had significant price volatility in the past 3 months compared to the SG market.
Volatility Over Time: 5G3's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 232 | Peng Tiam Ang | www.talkmed.com.sg |
TalkMed Group Limited, an investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, India, New Zealand, Australia, and the United States. It operates through two segments: Oncology Services; and Cellular and Gene Therapy Related Products and Services. The company offers medical oncology services in the areas of breast, colon, lung, liver, biliary and pancreatic, gastro-intestinal, head and neck, genitourinary and gynaecological, and haematology malignancies and brain cancers, as well as lymphoma and leukaemia.
TalkMed Group Limited Fundamentals Summary
| 5G3 fundamental statistics | |
|---|---|
| Market cap | S$597.44m |
| Earnings (TTM) | S$28.30m |
| Revenue (TTM) | S$79.12m |
21.3x
P/E Ratio7.6x
P/S RatioIs 5G3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5G3 income statement (TTM) | |
|---|---|
| Revenue | S$79.12m |
| Cost of Revenue | S$35.07m |
| Gross Profit | S$44.04m |
| Other Expenses | S$15.75m |
| Earnings | S$28.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.021 |
| Gross Margin | 55.67% |
| Net Profit Margin | 35.77% |
| Debt/Equity Ratio | 5.6% |
How did 5G3 perform over the long term?
See historical performance and comparison